Bleeding disorder refers to a condition that disrupts the process of coagulation of blood by preventing the formation of blood clots in hemophilic patients or patients with other bleeding disorders. Most of these bleeding disorders are inherited but some are acquired due to liver diseases, side effects of certain medications, low red blood cell count, vitamin K deficiency and others. The global bleeding disorders treatment market is expected to witness rapid growth during the forecast period due to increase in the number of people suffering from liver diseases, anemia, and other blood coagulation disorders.
The global bleeding disorders treatment market is driven by increase in the number of diagnosed patients with bleeding disorders, growth in awareness about bleeding disorders especially hemophilia, and proactive government initiatives in the developed countries towards establishing a wide network of diagnosis and treatment centers supplementing the market growth. However, lack of access to proper treatment due to high cost of medication and dearth of skilled health professionals restrain the market growth. Conversely, Asia-Pacific is expected to provide opportunities for the market growth due to increase in the awareness related to the treatment of bleeding disorders.
The global bleeding disorder market is segmented based on type, drug class, and region. On the basis of type, it is classified into hemophilia A, hemophilia B, Von Willebrand disease, and others. Based on drug, it is categorized into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others.
The coagulation factor concentrates segment is further divided into factor VIII, factor IX, factor for Von Willebrand disease, and activated prothrombin complex concentrate. On the basis of recombinant coagulation factor concentrates, the market is classified into factor VIII, factor for Von Willebrand disease, and factor IX. The market is analyzed based on region across North America, Europe, Asia-Pacific, and LAMEA further country level analysis of the region is provided to determine the market size and forecast for each segment and sub-segment of the market in various countries across the globe.
The key players profiled in the report include Novo Nordisk, Bayer AG, Baxter International Inc., Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Xenetic Biosciences, Inc., Bristol-Myers Squibb Company, Sanofi, Amgen, Inc., Janssen Global Services, LLC., and Bioverativ, Inc.
Key Benefits
- The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis of the industry to enable the stakeholders to capitalize on the prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled and their strategies have been analyzed thoroughly to understand the competitive outlook of the global market.
- Extensive analysis by product elucidates the use of various medicines for the treatment of hemophilia, clotting factor deficiency, and Von Willebrand disease.
Bleeding Disorders Treatment Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Drug Class |
|
 By Region |
|
 Key Market Players | Novo Nordisk, Pfizer, Inc., Sanofi, Bristol-Myers Squibb Company, Xenetic Biosciences, Inc., Amgen, Inc., Alnylam Pharmaceuticals, Inc., Bayer AG, Janssen Global Services, LLC., Baxter International Inc. |
Loading Table Of Content...
